{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:57:32Z","timestamp":1793044652236,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870831"],"award-info":[{"award-number":["81870831"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Project of Science and Technology Innovation","award":["2021ZD0201800"],"award-info":[{"award-number":["2021ZD0201800"]}]},{"name":"Key Project of Science and Technology Innovation","award":["2021ZD0201805"],"award-info":[{"award-number":["2021ZD0201805"]}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project","award":["TJYXZDXK-004A"],"award-info":[{"award-number":["TJYXZDXK-004A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Increasing evidence has shown the potential value of plasma biomarkers in Alzheimer\u2019s disease diagnosis. This study aimed to determine the diagnostic and differential values of emerging plasma biomarkers for different types of dementia in a Chinese population and to explore their cognitive correlations. One hundred twenty patients with dementia, including 51 Alzheimer\u2019s disease patients, 54 subcortical ischaemic vascular dementia (SIVD) patients and 15 frontotemporal lobar degeneration (FTLD) patients were recruited alongside 27 cognitively unimpaired (CU) control subjects. Global and domain-specific cognition was assessed in all participants by a battery of neuropsychological tests. Plasma amyloid-beta (\u0391\u03b2)42, A\u03b240 and total tau (in CU controls and Alzheimer\u2019s disease patients) and phosphorylated tau at threonine-181 (P-tau181), neurofilament light (NfL) and glial fibrillar acidic protein (GFAP) levels (in all participants) were measured using the single-molecule array platform. The levels of all biomarkers differed between Alzheimer\u2019s disease patients and CU controls, with P-tau181 and GFAP levels and the A\u03b242\/P-tau181 ratio best differentiating the two groups [area under the curve (AUC) = 0.966, 0.932 and 0.927, respectively]. P-tau181 and GFAP levels were greater in the Alzheimer\u2019s disease group than in the other two patient groups and showed the best performance in distinguishing Alzheimer\u2019s disease patients from SIVD (AUC = 0.922) and FTLD patients (AUC = 0.894), respectively. Moreover, compared with that in the CU group, the GFAP level was elevated in the SIVD group, and the NfL level was elevated in all patient groups. Compared with other single biomarkers, the plasma A\u03b242\/P-tau181 ratio correlated with broader cognitive domains, including global cognition [Mini-Mental Status Examination (MMSE), r = 0.314, P = 0.027; Montreal Cognitive Assessment (MoCA), r = 0.313, P = 0.043], memory (r = 0.339, P = 0.016), language (r = 0.333, P = 0.020), attention and information processing speed (r = 0.369, P = 0.008), executive function (r = 0.305, P = 0.031) and visuospatial function memory (r = 0.453, P = 0.001). P-tau181 was an optimal plasma biomarker for identifying Alzheimer\u2019s disease patients and differentiating Alzheimer\u2019s disease patients from SIVD and FTLD patients. Moreover, the GFAP level and the A\u03b242\/P-tau181 ratio showed potential diagnostic and progression monitoring value, respectively, for Alzheimer\u2019s disease patients.<\/jats:p>","DOI":"10.1093\/braincomms\/fcaf094","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:34:47Z","timestamp":1740461687000},"source":"Crossref","is-referenced-by-count":8,"title":["Plasma biomarkers for diagnosis and differentiation and their cognitive correlations in patients with Alzheimer\u2019s disease"],"prefix":"10.1093","volume":"7","author":[{"given":"Wenhao","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital , Tianjin 300052 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwei","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital , Tianjin 300052 ,","place":["China"]},{"name":"Department of Neurology, People's Hospital of Qingxian , Hebei 062650 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital , Tianjin 300052 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Medical University General Hospital Airport Site , Tianjin 300300 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Che","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital , Tianjin 300052 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital , Tianjin 300052 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9675-5322","authenticated-orcid":false,"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital , Tianjin 300052 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"6","key":"2025032523051048500_fcaf094-B1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer's disease: Recommendations of the international working group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol"},{"issue":"4","key":"2025032523051048500_fcaf094-B2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2025032523051048500_fcaf094-B3","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat Commun"},{"issue":"Suppl 2","key":"2025032523051048500_fcaf094-B4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40120-019-00164-5","article-title":"An update on blood-based markers of Alzheimer's disease using the SiMoA platform","volume":"8","author":"Li","year":"2019","journal-title":"Neurol Ther"},{"key":"2025032523051048500_fcaf094-B5","first-page":"483","article-title":"Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease","volume":"11","author":"Fossati","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"7","key":"2025032523051048500_fcaf094-B6","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jalz.2018.01.004","article-title":"Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers","volume":"14","author":"Hanon","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"3","key":"2025032523051048500_fcaf094-B7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer's disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat Med"},{"issue":"17","key":"2025032523051048500_fcaf094-B8","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"2025032523051048500_fcaf094-B9","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/ana.27008","article-title":"Head-to-head comparison of tau and amyloid positron emission tomography visual reads for differential diagnosis of neurodegenerative disorders: An international, multicenter study","volume":"96","author":"Soleimani-Meigooni","year":"2024","journal-title":"Ann Neurol"},{"issue":"7691","key":"2025032523051048500_fcaf094-B10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-beta biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"issue":"5","key":"2025032523051048500_fcaf094-B11","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ana.25334","article-title":"Plasma amyloid as prescreener for the earliest Alzheimer pathological changes","volume":"84","author":"Verberk","year":"2018","journal-title":"Ann Neurol"},{"issue":"1","key":"2025032523051048500_fcaf094-B12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13195-022-01093-6","article-title":"Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias","volume":"14","author":"Baiardi","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"2025032523051048500_fcaf094-B13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/jnnp-2021-327788","article-title":"Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy","volume":"93","author":"Chouliaras","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"2025032523051048500_fcaf094-B14","doi-asserted-by":"crossref","first-page":"e860","DOI":"10.1212\/WNL.0000000000201597","article-title":"Diagnostic performance and clinical applicability of blood-based biomarkers in a prospective memory clinic cohort","volume":"100","author":"Sarto","year":"2023","journal-title":"Neurology"},{"issue":"1","key":"2025032523051048500_fcaf094-B15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease","volume":"11","author":"Chatterjee","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"4","key":"2025032523051048500_fcaf094-B16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jalz.2019.09.004","article-title":"Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer's disease","volume":"16","author":"Elahi","year":"2020","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2025032523051048500_fcaf094-B17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","article-title":"Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment","volume":"13","author":"Cicognola","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"2025032523051048500_fcaf094-B18","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/alz.12700","article-title":"A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer's dementia: China aging and neurodegenerative initiative (CANDI) study","volume":"19","author":"Gao","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"12","key":"2025032523051048500_fcaf094-B19","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/clinchem\/hvab192","article-title":"Development of a plasma biomarker diagnostic model incorporating ultrasensitive digital immunoassay as a screening strategy for Alzheimer disease in a Chinese population","volume":"67","author":"Wu","year":"2021","journal-title":"Clin Chem"},{"issue":"1","key":"2025032523051048500_fcaf094-B20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13195-023-01246-1","article-title":"Reference intervals for plasma amyloid-beta, total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment","volume":"15","author":"Chen","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"2025032523051048500_fcaf094-B21","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1515\/cclm-2020-1030","article-title":"Reference values for plasma neurofilament light chain (NfL) in healthy Chinese","volume":"59","author":"Chen","year":"2021","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"2025032523051048500_fcaf094-B22","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"issue":"3","key":"2025032523051048500_fcaf094-B23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/WAD.0000000000000034","article-title":"Diagnostic criteria for vascular cognitive disorders: A VASCOG statement","volume":"28","author":"Sachdev","year":"2014","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"Pt 9","key":"2025032523051048500_fcaf094-B24","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"issue":"11","key":"2025032523051048500_fcaf094-B25","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants","volume":"76","author":"Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"issue":"2","key":"2025032523051048500_fcaf094-B26","doi-asserted-by":"crossref","first-page":"e14418","DOI":"10.1111\/cns.14418","article-title":"The value of FDG combined with PiB PET in the diagnosis of patients with cognitive impairment in a memory clinic","volume":"30","author":"Liu","year":"2024","journal-title":"CNS Neurosci Ther"},{"key":"2025032523051048500_fcaf094-B27","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fnagi.2020.00166","article-title":"TDP-43 is elevated in plasma neuronal-derived exosomes of patients with Alzheimer's disease","volume":"12","author":"Zhang","year":"2020","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"2025032523051048500_fcaf094-B28","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1021\/acschemneuro.2c00636","article-title":"Plasma core Alzheimer's disease biomarkers predict amyloid deposition burden by positron emission tomography in Chinese individuals with cognitive decline","volume":"14","author":"Ni","year":"2023","journal-title":"ACS Chem Neurosci"},{"issue":"3","key":"2025032523051048500_fcaf094-B29","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.neurobiolaging.2008.03.027","article-title":"Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment","volume":"31","author":"Hansson","year":"2010","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2025032523051048500_fcaf094-B30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jalz.2008.10.004","article-title":"Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease","volume":"5","author":"Roher","year":"2009","journal-title":"Alzheimers Dement"},{"issue":"8","key":"2025032523051048500_fcaf094-B31","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"3","key":"2025032523051048500_fcaf094-B32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/jnnp-2019-321954","article-title":"Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia","volume":"91","author":"Heller","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2025032523051048500_fcaf094-B33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13024-023-00605-8","article-title":"Plasma phospho-tau in Alzheimer's disease: Towards diagnostic and therapeutic trial applications","volume":"18","author":"Gonzalez-Ortiz","year":"2023","journal-title":"Mol Neurodegener"},{"issue":"12","key":"2025032523051048500_fcaf094-B34","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/cns.13962","article-title":"Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients","volume":"28","author":"Huang","year":"2022","journal-title":"CNS Neurosci Ther"},{"issue":"1","key":"2025032523051048500_fcaf094-B35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40364-022-00435-8","article-title":"Deamidation-related blood biomarkers show promise for early diagnostics of neurodegeneration","volume":"10","author":"Wang","year":"2022","journal-title":"Biomark Res"},{"issue":"10","key":"2025032523051048500_fcaf094-B36","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/alz.12332","article-title":"Plasma P-tau181 to Abeta42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease","volume":"17","author":"Chong","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2025032523051048500_fcaf094-B37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1373\/clinchem.2011.172676","article-title":"Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke","volume":"58","author":"Foerch","year":"2012","journal-title":"Clin Chem"},{"issue":"4","key":"2025032523051048500_fcaf094-B38","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/clinchem\/hvad018","article-title":"Plasma glial fibrillary acidic protein in the Alzheimer disease continuum: Relationship to other biomarkers, differential diagnosis, and prediction of clinical progression","volume":"69","author":"Shen","year":"2023","journal-title":"Clin Chem"},{"issue":"1","key":"2025032523051048500_fcaf094-B39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40035-023-00351-3","article-title":"Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia","volume":"12","author":"Zhu","year":"2023","journal-title":"Transl Neurodegener"},{"issue":"2","key":"2025032523051048500_fcaf094-B40","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3233\/JAD-180325","article-title":"Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment","volume":"67","author":"Oeckl","year":"2019","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"2025032523051048500_fcaf094-B41","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1212\/WNL.0000000000011226","article-title":"Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer disease","volume":"96","author":"Illan-Gala","year":"2021","journal-title":"Neurology"},{"issue":"7","key":"2025032523051048500_fcaf094-B42","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol"},{"issue":"1","key":"2025032523051048500_fcaf094-B43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40035-023-00371-z","article-title":"The potential impact of clinical factors on blood-based biomarkers for Alzheimer's disease","volume":"12","author":"Pan","year":"2023","journal-title":"Transl Neurodegener"},{"issue":"5","key":"2025032523051048500_fcaf094-B44","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"issue":"11","key":"2025032523051048500_fcaf094-B45","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.3390\/jcm8111893","article-title":"Associations between plasma biomarkers and cognition in patients with Alzheimer's disease and amnestic mild cognitive impairment: A cross-sectional and longitudinal study","volume":"8","author":"Tsai","year":"2019","journal-title":"J Clin Med"},{"issue":"1","key":"2025032523051048500_fcaf094-B46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13195-021-00864-x","article-title":"Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer's disease","volume":"13","author":"Xiao","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2025032523051048500_fcaf094-B47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40035-023-00365-x","article-title":"Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints","volume":"12","author":"Lu","year":"2023","journal-title":"Transl Neurodegener"},{"issue":"3","key":"2025032523051048500_fcaf094-B48","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","article-title":"Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline","volume":"140","author":"Rodriguez","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"3","key":"2025032523051048500_fcaf094-B49","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3233\/JAD-200475","article-title":"Plasma amyloid-beta biomarker associated with cognitive decline in preclinical Alzheimer's disease","volume":"77","author":"Lim","year":"2020","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"2025032523051048500_fcaf094-B50","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's association workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcaf094\/62138544\/fcaf094.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/7\/2\/fcaf094\/62138544\/fcaf094.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/7\/2\/fcaf094\/62138544\/fcaf094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T08:04:06Z","timestamp":1743235446000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcaf094\/8039212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcaf094","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"fcaf094"}}